SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 124 filers reported holding SYNDAX PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 0.54 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $530,604 | -16.7% | 36,543 | +20.0% | 0.00% | – |
| Q2 2023 | $637,276 | -85.6% | 30,448 | -85.5% | 0.00% | -100.0% |
| Q1 2023 | $4,438,431 | +765.6% | 210,153 | +943.1% | 0.00% | – |
| Q4 2022 | $512,742 | -72.1% | 20,147 | -73.6% | 0.00% | -100.0% |
| Q3 2022 | $1,836,000 | +323.0% | 76,391 | +239.0% | 0.00% | – |
| Q2 2022 | $434,000 | +40.9% | 22,535 | +26.9% | 0.00% | – |
| Q1 2022 | $308,000 | -20.2% | 17,756 | +0.8% | 0.00% | – |
| Q4 2021 | $386,000 | +0.8% | 17,608 | -11.9% | 0.00% | – |
| Q3 2021 | $383,000 | +25.6% | 19,993 | +12.8% | 0.00% | – |
| Q2 2021 | $305,000 | +41.2% | 17,717 | +83.6% | 0.00% | – |
| Q1 2021 | $216,000 | -96.9% | 9,648 | -96.9% | 0.00% | -100.0% |
| Q4 2020 | $6,949,000 | +619.4% | 312,463 | +377.5% | 0.00% | – |
| Q3 2020 | $966,000 | +46.4% | 65,438 | +8.8% | 0.00% | – |
| Q1 2020 | $660,000 | – | 60,152 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,025,000 | $21,648,000 | 10.42% |
| Foresite Capital Management IV, LLC | 875,000 | $18,480,000 | 9.59% |
| Kynam Capital Management, LP | 3,205,986 | $67,710,424 | 8.74% |
| Frazier Life Sciences Management, L.P. | 3,708,838 | $78,330,659 | 5.67% |
| ACUTA CAPITAL PARTNERS, LLC | 330,000 | $6,969,600 | 5.13% |
| Paradigm Biocapital Advisors LP | 2,274,512 | $48,037,693 | 4.55% |
| Eversept Partners, LP | 2,209,057 | $46,655,284 | 3.25% |
| DAFNA Capital Management LLC | 447,073 | $9,442,182 | 2.83% |
| COMMODORE CAPITAL LP | 853,884 | $18,034,030 | 2.75% |
| Avidity Partners Management LP | 3,865,300 | $81,635,136 | 2.71% |